A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612.

导出 OA

翻译打印收藏纠错

作者： Sarit,Assouline ^[1] ; Laura C,Michaelis ^[2] ; Megan,Othus ^[3] ; Annette E,Hay ^[4] ; Roland B,Walter ^[5] ; Meagan A,Jacoby ^[6] ; Mark A,Schroeder ^[6] ; Geoffrey L,Uy ^[6] ; Lisa Y,Law ^[7] ; Faisal,Cheema ^[8] ; Kendra L,Sweet ^[9] ; Adam S,Asch ^[10] ; Jijun Jane,Liu ^[11] ; Anna B,Moseley ^[2] ; Tracy,Maher ^[12] ; Laura L,Kingsbury ^[12] ; Min,Fang ^[5] ; Jerald,Radich ^[5] ; Richard F,Little ^[13] ; Harry P,Erba ^[14]

作者单位： McGill University - Jewish General Hospital, Montreal, Canada. ^[1] Medical College of Wisconsin, Milwaukee, WI, USA. ^[2] SWOG Statistics and Data Management Center, Seattle, WA, USA. ^[3] Queen's University, Kingston, Canada. ^[4] Fred Hutchinson Cancer Research Center, Seattle, WA, USA. ^[5] Washington University School of Medicine, St. Louis, MO, USA. ^[6] Kaiser Permanente NCAL, Roseville, CA, USA. ^[7] Kaiser Permanente, Santa Clara, CA, USA. ^[8] Moffitt Cancer Center, Tampa, FL, USA. ^[9] University of Oklahoma HSC, Oklahoma City, OK, USA. ^[10] Illinois CancerCare/Heartland NCORP, Peoria, IL, USA. ^[11] SWOG Data Operations Center/Cancer Research and Biostatistics, Seattle, WA, USA. ^[12] Cancer Therapy and Evaluation Program (CTEP), National Cancer Institute, Bethesda, MD, USA. ^[13] Duke University Medical Center, Duke Cancer Institute, Durham, NC, USA. ^[14]

主题词人类(Humans);中年人(Middle Aged);白血病, 粒-单核细胞, 慢性(Leukemia, Myelomonocytic, Chronic);阿扎胞苷(Azacitidine);骨髓增生异常综合征(Myelodysplastic Syndromes);白血病, 髓样, 急性(Leukemia, Myeloid, Acute)

DOI 10.1080/10428194.2022.2148212

PMID 36517990

发布时间 2024-02-02

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交